ReviewClinical and translational medicine2016
Therapeutic use of stem cells for cardiovascular disease.
Review in Clinical and translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 66 citations in OpenAlex.
- Comparative evaluation of cell types for endothelialization in cardiovascular tissue engineering.Iranian journal of basic medical sciences · 2026Review
- Comparison of Conventional Therapies With Stem Cell Therapy in the Treatment of Heart Disease.Cureus · 2025Article
- Structural investigation, computational analysis, and theoretical cryoprotectant approach of antifreeze protein type IV mutants.European biophysics journal : EBJ · 2024Article
- Application of adipose tissue-derived stem cell therapy with a clinically relevant dose does not significantly affect atherosclerotic plaque characteristics in a streptozotocin-induced hyperglycaemia mouse model.Journal of molecular and cellular cardiology plus · 2024Article
- hUMSCs Transplantation Regulates AMPK/NR4A1 Signaling Axis to Inhibit Ovarian Fibrosis in POI Rats.Stem cell reviews and reports · 2023Article
- A Comprehensive Cancer-Associated MicroRNA Expression Profiling and Proteomic Analysis of Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes.Tissue engineering and regenerative medicine · 2022Article
- Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Review
- Sequential transplantation of exosomes and mesenchymal stem cells pretreated with a combination of hypoxia and Tongxinluo efficiently facilitates cardiac repair.Stem cell research & therapy · 2022Article
- Review
- Stem cell therapy applied for digestive anastomosis: Current state and future perspectives.World journal of stem cells · 2022Article
- Intervention effects of traditional Chinese medicine on stem cell therapy of myocardial infarction.Frontiers in pharmacology · 2022Review
- Apelin Rejuvenates Aged Human Mesenchymal Stem Cells by Regulating Autophagy and Improves Cardiac Protection After Infarction.Frontiers in cell and developmental biology · 2021Article
- Stem Cell-Derived Exosomes Ameliorate Doxorubicin-Induced Muscle Toxicity through Counteracting Pyroptosis.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Direct conversion of human fibroblasts into therapeutically active vascular wall-typical mesenchymal stem cells.Cellular and molecular life sciences : CMLS · 2020Article
- miR-150 regulates endothelial progenitor cell differentiation via Akt and promotes thrombus resolution.Stem cell research & therapy · 2020Article
- Article
- Efficient Cardiac Differentiation of Human Amniotic Fluid-Derived Stem Cells into Induced Pluripotent Stem Cells and Their Potential Immune Privilege.International journal of molecular sciences · 2020Article
- Article
- Human Embryonic Stem Cell-Derived Cardiovascular Progenitors Repair Infarcted Hearts Through Modulation of MacrophagesAntioxidants & redox signaling · 2019Article
- Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure.Circulation research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stem cell treatments are a desirable therapeutic option to regenerate myocardium and improve cardiac function after myocardial infarction. Several different types of cells have been explored, each with their own benefits and limitations. Induced pluripotent stem cells possess an embryonic-like state and therefore have a high proliferative capacity, but they also pose a risk of teratoma formation. Mesenchymal stem cells have been investigated from both bone marrow and adipose tissue. Their immunomodulatory characteristics may permit the use of allogeneic cells as universal donor cells in the future. Lastly, studies have consistently shown that cardiac stem cells are better able to express markers of cardiogenesis compared to other cell types, as well improve cardiac function. The ideal source of stem cells depends on multiple factors such as the ease of extraction/isolation, effectiveness of engraftment, ability to differentiate into cardiac lineages and effect on cardiac function. Although multiple studies highlight the benefits and limitations of each cell type and reinforce the successful potential use of these cells to regenerate damaged myocardium, more studies are needed to directly compare cells from various sources. It is interesting to note that research using stem cell therapies is also expanding to treat other cardiovascular diseases including non-ischemic cardiomyopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.